data-prodige: RCT In Metastatic Pancreatic Cancer Comparing Two...
In BuyseTest: Generalized Pairwise Comparisons
prodige R Documentation
RCT In Metastatic Pancreatic Cancer Comparing Two Chemoterapy.
Description
Simulated data inspired from the PRODIGE trial comparing the survival of patients with metastatic pancreatic cancer
treated with FOLFIRINOX or gemcitabine .
-
id: study participant.
-
treatment: treatment arm: FOLFIRINOX (T) or gemcitabine (C).
-
OS: time from inclusion (say diagnosis) to end of follow-up.
-
statusOS: event triggering the end of follow-up: death (1), drop-out (0).
-
PFS: time from inclusion (say diagnosis) to progression of the disease or end of follow-up.
-
statusPFS: progression (1) or end of follow-up (0).
-
toxicity: most serious side effect observed during the follow-up (1 mild, 6 severe).
-
sex: male (M) or female (F)
Usage
data(prodige, package = "BuyseTest")
Format
An object of class data.table (inherits from data.frame) with 823 rows and 8 columns.
Author(s)
Brice Ozenne
References
Conroy, Thierry, et al. "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer" New England Journal of Medicine (2011) 364(19):1817-25. doi: 10.1056/NEJMoa1011923.
BuyseTest documentation built on April 12, 2025, 1:54 a.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| prodige | R Documentation |
RCT In Metastatic Pancreatic Cancer Comparing Two Chemoterapy.
Description
Simulated data inspired from the PRODIGE trial comparing the survival of patients with metastatic pancreatic cancer treated with FOLFIRINOX or gemcitabine .
-
id: study participant. -
treatment: treatment arm: FOLFIRINOX (T) or gemcitabine (C). -
OS: time from inclusion (say diagnosis) to end of follow-up. -
statusOS: event triggering the end of follow-up: death (1), drop-out (0). -
PFS: time from inclusion (say diagnosis) to progression of the disease or end of follow-up. -
statusPFS: progression (1) or end of follow-up (0). -
toxicity: most serious side effect observed during the follow-up (1 mild, 6 severe). -
sex: male (M) or female (F)
Usage
data(prodige, package = "BuyseTest")
Format
An object of class data.table (inherits from data.frame) with 823 rows and 8 columns.
Author(s)
Brice Ozenne
References
Conroy, Thierry, et al. "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer" New England Journal of Medicine (2011) 364(19):1817-25. doi: 10.1056/NEJMoa1011923.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.